Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Cannabinoids and glaucoma.

I Tomida¹, R G Pertwee, A Azuara-Blanco

¹Department of Ophthalmology, Aberdeen Royal Infirmary, University of Aberdeen, UK.

The British Journal of Ophthalmology

|April 20, 2004

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Cochrane Corner: evidence on the management of primary angle closure glaucoma.

Eye (London, England)·2022

Same author

Consensus generation of a minimum set of outcome measures for auditing glaucoma surgery outcomes-a Delphi exercise.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie·2018

Same author

A new approach for the management of primary angle-closure glaucoma after EAGLE trial.

Archivos de la Sociedad Espanola de Oftalmologia·2017

Same author

Monitoring ocular hypertension, how much and how often? A cost-effectiveness perspective.

The British journal of ophthalmology·2015

Same author

Design characteristic of randomised controlled trials for geographic atrophy in age-related macular degeneration: selection of outcomes and sample size calculation.

Eye (London, England)·2015

Same author

Cataract extraction and patient vision-related quality of life: a cohort study.

Eye (London, England)·2015

Same journal

Reference map of multimodal vision deficits in intermediate age-related macular degeneration: contrast sensitivity and low-contrast visual acuity.

The British journal of ophthalmology·2026

Same journal

Commentary on 'identifying patients with poor visual outcomes after primary rhegmatogenous retinal detachment surgery using machine learning'.

The British journal of ophthalmology·2026

Same journal

Automated deep learning-based retinoschisis and detachment volume measurement in pathological myopia with posterior scleral contraction.

The British journal of ophthalmology·2026

Same journal

Bacterial keratitis: a global review of current practices, challenges and innovations.

The British journal of ophthalmology·2026

Same journal

Real-world integration of an autonomous artificial intelligence system for diabetic retinopathy screening in an endocrinology outpatient clinic.

The British journal of ophthalmology·2026

Same journal

Maternal smoking during pregnancy: a risk factor for early childhood ophthalmologic conditions.

The British journal of ophthalmology·2026

See all related articles

Cannabinoids show promise for treating glaucoma, a leading cause of blindness. Research suggests these compounds can lower intraocular pressure and offer neuroprotection, making them a potential new therapeutic avenue.

Area of Science:

Ophthalmology
Pharmacology
Neuroscience

Background:

Glaucoma is a primary cause of global blindness.
Existing glaucoma treatments require improvement.
Cannabinoids possess properties beneficial for glaucoma management.

Purpose of the Study:

To review recent research on cannabinoid applications for glaucoma.
To highlight the therapeutic potential of cannabinoids in ophthalmology.

Main Methods:

Literature review of preclinical and clinical studies.
Analysis of cannabinoid effects on intraocular pressure (IOP).
Evaluation of cannabinoid neuroprotective mechanisms relevant to glaucoma.

Main Results:

Related Experiment Videos

Cannabinoids demonstrate significant IOP-lowering effects.
Neuroprotective properties of cannabinoids are evident.
Research indicates a potential role for cannabinoids in novel glaucoma therapies.

Conclusions:

Cannabinoids represent a promising area for glaucoma treatment development.
Further research is warranted to explore cannabinoid-based glaucoma therapies.